First patients test 'Switchable' Cancer-Fighting cells

NCT ID NCT06248086

Summary

This was the first-ever study in people of a new type of CAR-T cell therapy called ASP2802 for B-cell lymphoma that has come back or not responded to prior treatments. The main goal was to find a safe dose and understand how the body handles the treatment. The study was terminated early after enrolling only one participant.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Site AU61004

    Sydney, 3065, Australia

Conditions

Explore the condition pages connected to this study.